Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) March 08, 2021 07:00 ET | Source: Baudax Bio, Inc. Baudax Bio, Inc. Malvern, Pennsylvania, UNITED STATES MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro.